Vray stock price today
I believe this will put some some takeout value into VRAY stock, and that is what happened today.
![vray stock price today vray stock price today](https://www.dogsofthedow.com/wp-content/uploads/charts/vray-volatility.png)
Therefore, I view the VAR takeover as a validation MR-Linac, and therefore a validation of VRAY's strategy. Therefore, I think they read the tea leaves and decided to take the money from Siemens. They don't have the financial resources to buy VRAY themselves, and any crash program to build their own MR-Linac would take years and money. VAR does not have one and stands to lose share if that is where the market goes. I believe the mr-guided Linac is a better mousetrap. I suppose some people though their business would get more competitive with VAR in the hands of Siemens. I was surprised VRAY was down on Monday after the VAR buy out, but it certainly turned around today. (See ViewRay stock analysis on TipRanks) More
![vray stock price today vray stock price today](https://s3.tradingview.com/s/sDZK3jga_mid.png)
In addition, the $6.71 average price target implies 112% upside potential. 6 Buys and a single Hold issued in the last three months add up to a Strong Buy analyst consensus. Like O’Brien, other Wall Street analysts are staying on board. (To watch O’Brien’s track record, click here) At this target, shares could soar 89% in the next twelve months. Based on all of these factors, the five-star analyst maintained an Overweight rating and $6 price target.
#VRAY STOCK PRICE TODAY INSTALL#
He added, “We believe today’s dip represents a buying opportunity to investors willing to weather some quarterly volatility.”Īs recent investments from heavyweights Medtronic and Elekta boosted its capital, VRAY should be able to improve system install times as well as access potential hospital targets for the MRIdian system. “Although we do not expect this to be the last bump in the road, we remain highly confident in the utility of the MRIdian as the best technology to treat cancer patients, and we believe it will yield significant share-taking over the next couple of years,” O’Brien commented. Piper Sandler’s Matthew O'Brien did acknowledge the result was unexpected “as momentum in the order book appeared to have been building with eight orders (three upgrades) last quarter.” However, he argues that the soft order figure is indicative of “standard lumpiness capital equipment sales”, which should improve in the coming quarters. That isn’t to say investors should give up on the healthcare name. It also didn’t help that VRAY burned through about $3 million in cash. As this is down from $49 million in the prior-year quarter, it’s no wonder investors have been concerned. However, new orders largely disappointed, with this figure coming in at $21 million. VRAY announced that it expects quarterly sales of $17 million, landing very close to the consensus estimate. The share price decline comes on the heels of its preliminary Q4 results. With this groundbreaking offering, why have shares dipped 25% year-to-date? Its approach uses MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. ViewRay is focused on giving clinicians new and more effective ways to treat cancer using radiation.